← Back to Search

Procedure

rTMS + Text4Support for Depression

N/A

Recruiting

Led By Vincent Agyapong, MD, Ph.D

Research Sponsored by University of Alberta

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Study Summary

This trial is testing whether combining rTMS sessions with Text4Support is more effective than rTMS sessions alone in treating mental illness.

Who is the study for?

This trial is for adults over 18 with Major Depressive Disorder (MDD) who haven't improved after trying at least two antidepressant treatments. They must understand English, be able to use a smartphone for texts, and give written consent. It's not for those under 18, pregnant or breastfeeding women, people with learning disabilities, psychotic disorders, personality disorders that affect study participation, involvement in other trials recently, or certain neurological conditions.Check my eligibility

What is being tested?

The trial tests if adding Text4Support (a text messaging support system) to repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation treatment for depression, helps more than rTMS alone. Participants are randomly placed into one of these two groups and followed up at intervals after the six-week active treatment phase.See study design

What are the potential side effects?

Common side effects of rTMS include discomfort at the treatment site during sessions, headache afterwards and rarely seizures. The addition of Text4Support isn't expected to introduce physical side effects but may impact participants' emotional state due to content.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The Patient Health Questionnaire (PHQ-9)

Secondary outcome measures

Columbia Suicide Severity Rating Scale

Generalized Anxiety Disorders Scale (GAD-7)

The World Health Organization - Five Well-Being Index (WHO-5)

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Enrolment in rTMS sessions plus Text4SupportExperimental Treatment1 Intervention

Participants in the rTMS plus Text4Support group of the study would be assisted by a study team member assigned that purpose to register onto the Text4Support program. The process would require all participants to input their phone numbers into the Text4Support platform that will be used to deliver the daily messages. Starting a day after enrollment, participants will receive daily supportive text messages designed by mental health therapists, clinical psychologists, psychiatrists, and mental health service users. These messages are based on cognitive behavior therapy principles crafted to enhance positively the mood of its users with depressive symptoms and other related mental health problems of concern. The messages will be pre-programmed into a software program that will deliver the messages to participants automatically to the participants' mobile phones at 10 AM (Mountain Time) and 12 PM (Atlantic Time), and each participant will receive these messages continuously for 6 weeks.

Group II: Enrolment in rTMS sessions aloneActive Control1 Intervention

All study participants will be scheduled to receive 30 sessions of rTMS treatment for 6 weeks as pre-established by the Alberta Health Services Strategic Clinical Network for Addiction and Mental Health and Nova Scotia Health.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor

889 Previous Clinical Trials

384,934 Total Patients Enrolled

18 Trials studying Depression

8,678 Patients Enrolled for Depression

Vincent Agyapong, MD, Ph.DPrincipal InvestigatorDivision of Community Psychiatry, University of Alberta

Media Library

Repetitive Transcranial Magnetic Stimulation (rTMS) (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05570344 — N/A

Depression Clinical Trial 2023: Repetitive Transcranial Magnetic Stimulation (rTMS) Highlights & Side Effects. Trial Name: NCT05570344 — N/A

Repetitive Transcranial Magnetic Stimulation (rTMS) (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05570344 — N/A

Depression Research Study Groups: Enrolment in rTMS sessions plus Text4Support, Enrolment in rTMS sessions alone

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there an ongoing enrollment period for this clinical investigation?

"According to clinicaltrials.gov, the recruitment period for this trial is closed as it was last edited on November 1st 2022. Nevertheless, there are currently 1295 other medical studies that actively require patients now."

Answered by AI